Concomitant Chemoradiotherapy With Mitomycin C and Cisplatin in Advanced Unresectable Carcinoma of the Head and Neck: Phase I-II Clinical Study

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 2, 2008, Pages 365-372

  Strojan, Primož ^a   Karner, Katarina ^a   Šmid, Lojze ^b   Šoba, Erika ^a   Fajdiga, Igor ^b   Jančar, Boris ^a   Aničin, Aleksandar ^b   Budihna, Marjan ^a   Zakotnik, Branko ^a  

^a INSTITUTE OF ONCOLOGY   (Slovenia)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

clinical trial; concomitant chemoradiotherapy; Head and neck cancer; squamous cell carcinoma; unresectable cancer

Indexed keywords

CLINICAL TRIAL; CONCOMITANT CHEMORADIOTHERAPY; HEAD AND NECK CANCER; SQUAMOUS CELL CARCINOMA; UNRESECTABLE CANCER;

PLATINUM COMPOUNDS;

CISPLATIN; MITOMYCIN C;

AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRONCHOPNEUMONIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG DOSE ESCALATION; DRUG EFFICACY; DYSPHAGIA; ESOPHAGUS STRICTURE; FEMALE; FOLLOW UP; HEAD AND NECK CARCINOMA; HEARING IMPAIRMENT; HUMAN; HYPOKALEMIA; HYPOPHARYNX CANCER; INFECTION; LARYNX CARCINOMA; LARYNX EDEMA; LARYNX STENOSIS; LIVER TOXICITY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; METASTASIS; MUCOSA INFLAMMATION; NECK DISSECTION; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; OROPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; SIDE EFFECT; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT FAILURE; TREATMENT RESPONSE; ULCER PERFORATION; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; SURVIVAL ANALYSIS;

EID: 51449093748     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.12.060     Document Type: Article

References (46)

1. Fu K.K., Phillips T.L., Silverberg I.J., et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group randomized trial. J Clin Oncol 5 (1987) 1410-1418
2. Merlano M., Benasso M., Corvo R., et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 88 (1996) 583-589
3. Adelstein D.J., Li Y., Adams G.L., et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21 (2003) 92-98
4. Zorat P.L., Paccagnella A., Cavaniglia G., et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10-year follow-up. J Natl Cancer Inst 96 (2004) 1714-1717
5. Budihna M., Skrk J., Smid L., et al. Tumor cell repopulation in the rest interval of split-course radiation treatment. Strahlentherapie 156 (1980) 402-408
6. Withers H.R., Taylor J.M.G., and Maciejewski B. The hazard of accelerated tumour clonogen repopulation during radiotherapy. Acta Oncol 27 (1988) 131-146
7. Gray L.H., Conger A.D., Ebert M., et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 26 (1953) 638-648
8. Bourhis J., Overgaard J., Audry H., et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 368 (2006) 843-854
9. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
10. Bourhis J., Amand C., and Pignon J.P. Update of MACH-HN (Meta-Analysis of Chemotherapy in Head & Neck Cancer) database focused on concomitant chemoradiotherapy (Abstr.). Proc Am Soc Clin Oncol 22 (2004) S489
11. Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumours. Oncol Res 6 (1994) 509-518
12. Strojan P. Cisplatin based chemotherapy: The only alternative in chemoradiation of head and neck cancer? Experience of the Institute of Oncology Ljubljana, Slovenia. Rep Pract Oncol Radiother 12 (2007) 329-337
13. Garden A.S., Glisson B.S., Ang K.K., et al. Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinoma of the head and neck: Toxicities and responses. J Clin Oncol 17 (1999) 2390-2395
14. Sobin L.H., and Wittekind Ch. International Union Against Cancer (UICC): TNM classification of malignant tumours. 6th ed. (2002), Wiley-Liss, New York p. 22-42
15. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 53 (1958) 457-481
16. Horsman M.R. Measurement of tumor oxygenation. Int J Radiat Oncol Biol Phys 42 (1998) 701-704
17. Sartorelli A.C., Hodnick W.F., Belcourt M.F., et al. Mitomycin C-a prototype bioreductive agent. Oncol Res 6 (1994) 501-508
18. Budihna M., Šoba E., Šmid L., et al. Inoperable oropharyngeal carcinoma treated with concomitant irradiation, mitomycin C and bleomycin-long term results. Neoplasma 52 (2005) 165-173
19. Kocher M., and Treuer H. Reoxygenation of hypoxic cells by tumor shrinkage during irradiation. A computer simulation. Strahlenther Oncol 171 (1995) 219-230
20. Dobrowsky W., Dobrowsky E., and Rauth A.M. Mode of interaction of 5-fluorouracil, irradiation and mitomycin C: In vitro studies. Int J Radiat Oncol Biol Phys 22 (1992) 875-880
21. Smid L., Lesnicar H., Zakotnik B., et al. Radiotherapy, compared with simultaneous chemotherapy with mitomycin C and bleomycin for inoperable head and neck cancer: Preliminary report. Int J Radiat Oncol Biol Phys 32 (1995) 769-775
22. Zakotnik B., Šmid L., Budihna M., et al. Concomitant radiotherapy with mitomycin C and bleomycin compared with radiotherapy alone in inoperable head and neck cancer: Final report. Int J Radiat Oncol Biol Phys 41 (1998) 1121-1127
23. Haffty B.G., Son Y.H., Papac R., et al. Chemotherapy as an adjunct to radiation to the treatment of squamous cell carcinoma of the head and neck: Results of the Yale mitomycin randomized trials. J Clin Oncol 15 (1997) 268-276
24. Dobrowsky W., and Naudé J. Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Radiother Oncol 57 (2000) 119-124
25. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: Final results of the Radiotherapy Cooperative Clinical Trial Group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol 23 (2005) 1125-1135
26. Knee R., Fields R.S., and Peters L.J. Concomitant boost radiotherapy for advanced squamous cell carcinoma of the head and neck. Radiother Oncol 4 (1985) 1-7
27. Ang K.K., Peters L.J., Weber R.S., et al. Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 19 (1990) 1339-1345
28. Corry J., Rischin D., Smith J.G., et al. Radiation with concurrent late chemotherapy intensification ("chemoboost") for locally advanced head and neck cancer. Radiother Oncol 54 (2000) 123-127
29. Garden A.S., Harris J., Vokes E.E., et al. Preliminary results of Radiation Therapy Oncology Group 97-03: A randomized phase II trial of concurrent radiation and chemotherapy for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 22 (2004) 2856-2864
30. Rischin D., Peters L., Fisher R., et al. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J Clin Oncol 23 (2005) 79-87
31. Forastiere A.A., Belliveau J.F., Goren M.P., et al. Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cisdiamminedichloroplatinum (II) in head and neck cancer patients. Cancer Res 48 (1988) 3869-3874
32. Schwahofer J.H., Crooijmans R.P., Hoogenhout J., et al. Effectiveness in inhibition of recovery of cell survival by cisplatin and carboplatin: Influence of treatment sequence. Int J Radiat Oncol Biol Phys 20 (1991) 1235-1241
33. Schaake-Koning C., van den Bogaert W., Dalesio O., et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl J Med 326 (1992) 524-530
34. Glicksman A.S., Slotman G., Doolittle III C., et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 30 (1994) 1043-1050
35. Jeremic B., Milicic B., Dagovic A., et al. Radiation therapy with or without concurrent low-dose daily chemotherapy in locally advanced, nonmetastatic squamous cell carcinoma of the head and neck. J Clin Oncol 22 (2004) 3540-3548
36. Hehr T., Classen J., Welz S., et al. Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study. Radiother Oncol 80 (2006) 33-38
37. Ang K.K. Concurrent radiation chemotherapy for locally advanced head and neck carcinoma: Are we addressing burning subject?. J Clin Oncol 23 (2004) 4605-4607
38. Kasibhatla M., Kirkpatrick J.P., and Brizel D.M. How much radiation is the chemotherapy worth in advanced head and neck cancer?. Int J Radiat Oncol Biol Phys 68 (2007) 1491-1495
39. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 338 (1998) 1798-1804
40. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171
41. Bucci M.K., Rosenthal D.I., Hershock D., et al. Final report of a pilot trial of accelerated radiotherapy plus concurrent 96-hour infusional paclitaxel for locally advanced head and neck cancer. Am J Clin Oncol 27 (2004) 595-602
42. Beckmann G.K., Hoppe F., Pfreundner L., et al. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 27 (2005) 36-43
43. Medina J.A., Rueda A., de Pasos A.S., et al. A phase II study of concomitant boost radiation plus concurrent weekly cisplatin for locally advanced unresectable head and neck carcinomas. Radiother Oncol 79 (2006) 34-38
44. Allen A.M., Elshaikh M., Worden F.P., et al. Acceleration of hyperfractionated chemoradiation regimen for advanced head and neck cancer. Head Neck 29 (2007) 137-142
45. Adelstein D.J., and LeBlanc M. Does induction chemotherapy have a role in the management of locally advanced squamous cell head and neck cancer?. J Clin Oncol 24 (2006) 2624-2628
46. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm. J Clin Oncol 24 (2006) 1072-1078